Karyopharm Therapeutics (KPTI) Interest Coverage Ratio (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Interest Coverage Ratio came in at 1.41 in Q4 2025, up 49.35% YoY from 0.95 in Q4 2024, and down 411.99% on a QoQ basis from 0.28 in Q3 2025.
Karyopharm Therapeutics (KPTI) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Interest Coverage Ratio data on file, last reported at 1.41 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 49.35% year-over-year to 1.41 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.97 (up 38.28% YoY) and the FY2025 annual result came in at 0.29, down 8.44% from the prior year.
- Interest Coverage Ratio eased to 1.41 in Q4 2025, from 0.28 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 18.15 in Q4 2021 to a low of 14.61 in Q4 2023.
- A 5-year average of 3.86 and a median of 5.08 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio surged 127.78% — and 2023, when it plunged 785.14%.
- Tracing KPTI's Interest Coverage Ratio over 5 years: stood at 18.15 in 2021, then plunged by 109.1% to 1.65 in 2022, then sank by 785.14% to 14.61 in 2023, then soared by 80.9% to 2.79 in 2024, then surged by 49.35% to 1.41 in 2025.
- The last three Interest Coverage Ratio figures came in at 1.41 (Q4 2025), 0.28 (Q3 2025), and 2.17 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | -1.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.79 |
| Dec 31, 2025 | -1.41 |
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -2.17 |
| Mar 31, 2025 | -3.02 |
| Dec 31, 2024 | -2.79 |
| Sep 30, 2024 | -2.31 |
| Jun 30, 2024 | -3.14 |
| Mar 31, 2024 | -5.74 |
| Dec 31, 2023 | -14.61 |
| Sep 30, 2023 | -5.15 |
| Jun 30, 2023 | -5.11 |
| Mar 31, 2023 | -5.37 |
| Dec 31, 2022 | -1.65 |
| Sep 30, 2022 | -5.04 |
| Jun 30, 2022 | -6.80 |
| Mar 31, 2022 | -5.17 |
| Dec 31, 2021 | 18.15 |
| Sep 30, 2021 | -5.47 |
| Jun 30, 2021 | -9.81 |